Scientists discover another hormone that could revolutionize weight loss drugs
Amylin works similarly to certain existing GLP-1 drugs on the market.
Even if weight loss drugs like Ozempic and Wegovy are medical breakthroughs, scientists continue to work on the next generation of Obesity drugs . The latest discovery involves another hormone known as Amylin, which, according to scientists, could help revolutionize weight loss drugs as we know them.
In relation: Why up to 75% of people in weight loss cease to take them, says cardiologist .
Amyline operates similarly to semaglutides in the body.
In an article published in the journal Scientific signaling On August 19, researchers from the University of Oklahoma announced that they had finally discovered new information on how the amylin hormone was activated in the body, which makes it more accessible for the next generation of pharmaceutical development for weight management medicines.
As a rule, the pancreas AMYLIN product and secrete Alongside insulin whenever a person eats, according to a press release. The hormone not only helps regulate blood sugar, but it also helps to control appetite and feelings of hunger.
Overall, it is similar to the semaglutide used by GLP-1 style medicines such as Wegovy and Ozempic, which interact with the same family of receptors in the brain.
"There has been a lot of interest in the pharmaceutical industry to develop new obesity drugs", " Sandra Gostynska , said the main author of the newspaper and doctoral student at the University of Oklahoma, in a press release. "What we have done is the field of new tools in the field to understand how a drug can affect amyline receptors."
The new research has produced significant results for weight loss.
Scientists won at least two important results from the research document. The first concerns our understanding of the three Amyline receptors, which seem similar but are in fact composed of slightly different subcompants who make them more complicated.
The team compares this to a group of people who can wear an identical outfit, but each has unique accessories that differentiate them from others. They explained that this breakthrough will allow them to focus on the required elements (which in this case controls appetite) to help minimize the side effects of future drugs while maximizing efficiency.
The second major to remember also concerned the receivers' subunits, but was focused on the future potential of drugs to "collect the subunits or separate them". Researchers said this new understanding could help engineering new drugs to produce different results.
"This article shows the new biochemical and pharmacological methods that we have developed which will allow for the first time in the field, to understand exactly what development drugs do in each of the three Amyline receivers", " AUGEN PIOSZAK , Said the PHD, the main author of the newspaper and associate professor of biochemistry and physiology at the University of Oklahoma College of Medicine, in the press release.
“Amyline receivers are very complicated, and everyone has very different and unique properties. What we have discovered has escaped researchers for many years, and we think that our results will advance the development of drugs, "added Pioszak.
In relation: Is the little-known supplement called "Ozempic de la Nature"-Does it really work for weight loss?
Companies are already trying to develop drugs based on Amylin.
The latest discoveries could considerably accelerate the development of a new style of medication already underway. Last September, the Pharmaceutical and Developer Ozempic, Novo Nordisk, announced that it had been successful in a phase I test of a New obesity pill Amyline targeting known as AmyCritine, stat.
The results revealed that patients taking a daily dose of 50 mg of the drug experienced weight loss of 10.4% during the trial period of about three months. Those who take a double dose have seen even more books with a weight loss of 13.1%, compared to a weight loss of 1.1% for participants taking a placebo pill.
Scientists involved in the latest research document say that their results could help others better understand how to progress with their next generation of drugs, throwing an essential light on a subject previously unknown.
"We believe that our results will improve the study of drugs because what pharmaceutical and biotechnological companies want to know is what their medication does in each Amyline receiver," Pioszak said in the press release. "Now we have a method to answer these questions that were previously unanswered."
